Vedolizumab (Entyvio) for Ulcerative Colitis: A Patient Guide

Vedolizumab, sold under the brand name Entyvio, is a biologic medication approved for moderate to severe ulcerative colitis. Unlike other biologics that broadly suppress the immune system throughout the entire body, vedolizumab works specifically in the gut — making it a highly targeted option with a favorable safety profile that appeals to many gastroenterologists and patients. This guide explains how it works, what to expect during treatment, the side effects to be aware of, and what questions to ask your doctor before starting.

How Does Vedolizumab Work?

Vedolizumab belongs to a class of biologics called integrin receptor antagonists. Its mechanism is distinct from TNF inhibitors and other commonly used biologics, and understanding the difference helps explain why it is prescribed and what its advantages are.

The medication targets a protein called alpha-4-beta-7 integrin, which acts as a kind of address label on certain immune cells. This integrin directs those inflammatory immune cells specifically to the lining of the gut. By blocking this protein, vedolizumab prevents inflammatory cells from entering the intestinal tissue — cutting off the supply of cells that drive the inflammation causing UC symptoms.

The key feature of this mechanism is its gut-selective action. Vedolizumab does not block immune activity throughout the rest of the body — it is specifically targeted to the mucosal lining of the gastrointestinal tract. This is in contrast to TNF inhibitors like infliximab and adalimumab, which reduce inflammation across multiple organ systems. The gut-selective mechanism means that vedolizumab does not broadly suppress the immune system, which has important implications for the side effect and infection risk profile.

Vedolizumab is available in two forms. The original formulation is given as an intravenous (IV) infusion at an infusion center. A subcutaneous injection formulation is now also available, allowing patients to self-inject at home after completing the initial induction doses.

• Targets alpha-4-beta-7 integrin — a protein that guides immune cells into the gut lining
• Blocks inflammatory immune cells specifically from entering intestinal tissue
• Gut-selective mechanism — does not suppress systemic immunity like TNF inhibitors
• Available as IV infusion or subcutaneous self-injection

Who Is Vedolizumab Prescribed For?

Vedolizumab is approved for adults with moderate to severe active UC who have not achieved adequate control with conventional therapies. In practice, it is used in several specific clinical situations.

The most common scenario is a patient whose disease has not responded adequately to mesalamine and corticosteroids — either the medications did not work, worked only partially, or the patient became dependent on steroids they cannot safely continue long-term.

Vedolizumab is also commonly used for patients who have tried and failed TNF inhibitors (infliximab or adalimumab), or who experienced unacceptable side effects on those medications. Because its mechanism is entirely different from TNF inhibition, there can be a meaningful response to vedolizumab even in patients who did not benefit from other biologics.

Its gut-selective profile makes it a particularly attractive option in certain populations where broader immunosuppression is a concern. Older patients, those with a history of recurring infections, or patients where a systemic immune suppression carries elevated risk are often good candidates. The same logic applies to patients with a history of certain cancers, where the more targeted action of vedolizumab is preferable.

Vedolizumab is also approved for Crohn’s disease, making it an option for patients with an uncertain IBD classification or for those whose gastroenterologist wants to select a medication that covers both diagnoses.

How Is Vedolizumab Given?

Understanding the dosing schedule before you start helps set expectations and reduce anxiety about what the treatment process looks like.

IV infusion protocol: The induction schedule involves infusions at week 0, week 2, and week 6. After induction, maintenance infusions are given every 8 weeks. Each infusion takes approximately 30 minutes and is administered in a hospital infusion unit or outpatient infusion center. You will be monitored during and briefly after the infusion. Most patients find the process straightforward — many bring a book or use the time to catch up on tasks during the infusion.

Subcutaneous injection protocol: After completing the initial IV induction doses, patients who have demonstrated a response may have the option of transitioning to subcutaneous self-injection every two weeks. The injection is given using a pre-filled pen device, similar to devices used for other self-injected biologics. Many patients prefer this option because it eliminates the need for regular infusion center visits.

Your gastroenterologist will discuss which administration route is most appropriate for your situation. Factors include your preference, your response to induction, your access to an infusion center, and your comfort with self-injection.

How Long Does Vedolizumab Take to Work?

One of the important conversations to have before starting vedolizumab is about its onset of action — because it works more slowly than some other biologic options, and understanding this prevents unnecessary early discontinuation.

While some patients notice improvement within the first few weeks, vedolizumab’s typical initial response time is 6 to 14 weeks from the first dose. This is longer than TNF inhibitors like infliximab, which can show clinical response in some patients within two to four weeks. The reason for the slower onset is likely related to the mechanism — reducing the migration of immune cells into the gut takes time to translate into reduced mucosal inflammation.

Week 14 is the standard clinical assessment point. Your gastroenterologist will evaluate your symptoms, and in many cases arrange a flexible sigmoidoscopy or other assessment, to determine whether you are responding to the medication. Patients who are responding at week 14 continue on to maintenance dosing. Patients who have not shown adequate response may be switched to a different therapy.

The most important thing to understand is that stopping vedolizumab before week 14 because symptoms have not yet improved would be premature in most cases. If you are concerned about your progress at any point, the conversation to have is with your gastroenterologist — not a unilateral decision to stop.

• Typical initial response: 6–14 weeks from first dose
• Slower onset than TNF inhibitors — this is expected and normal
• Week 14 is the formal clinical assessment point for response
• Do not stop without discussing with your GI doctor first

Vedolizumab Side Effects

Vedolizumab’s gut-selective mechanism gives it a side effect profile that many patients and doctors find more reassuring than systemically acting biologics, but it is not side-effect free.

Common side effects that occur more frequently than with placebo in clinical trials include nasopharyngitis (common cold symptoms), headache, joint pain (arthralgia), nausea, and fatigue. Most of these are mild and manageable, and many improve after the first few infusions as the body adjusts.

Infusion reactions can occur during or shortly after IV dosing. They range from mild flushing or itching to more significant reactions. Infusion centers are equipped to manage these, and premedication is sometimes given for patients who have previously experienced a reaction. The subcutaneous form has its own injection-site reactions, which are generally mild.

Serious infections are a concern with any biologic, and vedolizumab is no exception. However, because it does not suppress systemic immunity in the same way as TNF inhibitors, the risk of serious non-gastrointestinal infections — such as tuberculosis or opportunistic infections — appears to be lower. Routine TB screening before starting is still performed as a precaution.

Progressive multifocal leukoencephalopathy (PML), a serious brain infection caused by the JC virus, has been reported in extremely rare cases in patients taking vedolizumab. The risk appears to be very low — far lower than with natalizumab, an integrin inhibitor used for multiple sclerosis — but it is monitored for as a precaution. Your doctor will discuss this in the context of your individual risk profile.

Overall, vedolizumab is widely considered one of the safest biologics available for UC, which is a meaningful consideration for patients who will be on the medication long-term.

Vedolizumab vs Other Biologics

Understanding how vedolizumab fits into the broader treatment landscape can help you have a more informed conversation with your gastroenterologist about whether it is the right choice for your situation.

Versus TNF inhibitors (infliximab, adalimumab): TNF inhibitors act faster and have a longer track record in UC. Vedolizumab has a more favorable safety profile due to gut selectivity and is a strong option for patients who have not responded to TNF inhibitors or for those where systemic immunosuppression is a concern. The choice between them is often determined by the patient’s prior treatment history.

Versus ustekinumab: Ustekinumab (Stelara) targets IL-12 and IL-23, different inflammatory pathways. Both are considered gut-friendly options, and the choice between them is often individualized. Vedolizumab has more efficacy data specific to UC; ustekinumab is also approved for Crohn’s and psoriasis.

Versus JAK inhibitors (tofacitinib, upadacitinib): JAK inhibitors are oral pills rather than infusions or injections — a meaningful convenience advantage. They work faster and have shown strong efficacy in biologic-failed patients. However they carry a black box warning that vedolizumab does not. The choice between an oral JAK inhibitor and vedolizumab depends on the patient’s risk profile, preferences, and disease history.

For a side-by-side comparison of all major UC medications — including biologics and JAK inhibitors — see our biologics for UC guide and the full UC treatment comparison.

Questions to Ask Your Doctor About Vedolizumab

Going into a conversation about starting vedolizumab with specific questions helps ensure you understand what you are committing to and what to watch for.

• Am I a good candidate for vedolizumab given my treatment history? Ask specifically whether your prior medication history supports or complicates this choice.
• Should I start with IV infusions or is subcutaneous an option from the beginning? Understand which route is recommended for your case and what the transition plan looks like.
• How will we know if it is working? Ask what the assessment criteria are at week 14 and what a positive response looks like clinically.
• What happens if I do not respond by week 14? Know the plan B before you need it.
• Is there a patient assistance program available? Vedolizumab is expensive. Most manufacturers offer patient support programs that can significantly reduce out-of-pocket costs — ask your GI team or look for a nurse navigator or patient services contact.

Medical Disclaimer

This article is for educational purposes only and does not constitute medical advice. Whether vedolizumab is the right medication for your UC depends on your individual medical history, prior treatment response, and other factors that only your gastroenterologist can properly evaluate. Always consult your care team before starting, stopping, or changing any medication.